Central nervous system disorder specialist Chelsea Therapeutics International on Thursday said it had signed up to a bid from Denmark's H. Lundbeck that values its stock at up to $658 million.

Chelsea Therapeutics (CHTP) soared Thursday amid news that Danish pharmaceutical company H. Lundbeck would takeover the company for up to $658 million.

Chelsea CEO Joe Oliveto and his team deserve a lot of credit for cleaning up some messy Northera clinical trials, scoring at the FDA advisory panel, securing the drug's approval and now delivering on the exit strategy that everyone wanted.

Cramer is staying away from Solazyme but thinks Retrophin is too frothy.

Netflix layoffs continue as the streaming giant executes a plan to cope with slow revenue growth.

As mortgage rates hit fresh highs, there's something unusual going on with the real estate market.

Disney, JP Morgan Chase, and outgoing Meta COO Sheryl Sandberg are just a few speaking out against the ruling.